Fuso Pharmaceutical Industries (TSE:4538) Piotroski F-Score: 5 (As of Jun. 29, 2026) — 17% Below Median


TSE:4538 Fuso Pharmaceutical Industries Ltd TSE:4538
51 GF Score
Price 円2,071.00
GF Value 円2,540.99
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Fuso Pharmaceutical Industries Piotroski F-Score?

Fuso Pharmaceutical Industries TSE:4538 +0.34% 51 Piotroski F-Score is 5 as of Jun. 29, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates TSE:4538 with a GF Score™ of 51/100 and a GF Value™ of 円2,540.99 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 978 Drug Manufacturers companies, Fuso Pharmaceutical Industries ranks better than 61.66% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Fuso Pharmaceutical Industries has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Fuso Pharmaceutical Industries's Piotroski F-Score or its related term are showing as below:

TSE:4538' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Fuso Pharmaceutical Industries was 8. The lowest was 4. And the median was 6.

Fuso Pharmaceutical Industries  (TSE:4538) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Fuso Pharmaceutical Industries Piotroski F-Score Related Terms


Fuso Pharmaceutical Industries Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Fuso Pharmaceutical Industries's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fuso Pharmaceutical Industries Piotroski F-Score Chart

Fuso Pharmaceutical Industries Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 8.00 4.00 4.00 5.00

Fuso Pharmaceutical Industries Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4.00 0.00 0.00 5.00

TSE:4538 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fuso Pharmaceutical Industries's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuso Pharmaceutical Industries Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fuso Pharmaceutical Industries's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Fuso Pharmaceutical Industries's Piotroski F-Score falls into.


TSE:4538
51GF Score
Fuso Pharmaceutical Industries Ltd TSE:4538
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 円2,011 Mil.
Cash Flow from Operations was 円-6,224 Mil.
Revenue was 円62,307 Mil.
Gross Profit was 円15,995 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (81729 + 90323) / 2 = 円86026 Mil.
Total Assets at the begining of this year (Mar25) was 円81,729 Mil.
Long-Term Debt & Capital Lease Obligation was 円1,858 Mil.
Total Current Assets was 円57,336 Mil.
Total Current Liabilities was 円51,684 Mil.
Net Income was 円-3,288 Mil.

Revenue was 円60,562 Mil.
Gross Profit was 円16,532 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (75802 + 81729) / 2 = 円78765.5 Mil.
Total Assets at the begining of last year (Mar24) was 円75,802 Mil.
Long-Term Debt & Capital Lease Obligation was 円2,462 Mil.
Total Current Assets was 円48,342 Mil.
Total Current Liabilities was 円44,131 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Fuso Pharmaceutical Industries's current Net Income (TTM) was 2,011. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Fuso Pharmaceutical Industries's current Cash Flow from Operations (TTM) was -6,224. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=2011/81729
=0.02460571

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-3288/75802
=-0.04337616

Fuso Pharmaceutical Industries's return on assets of this year was 0.02460571. Fuso Pharmaceutical Industries's return on assets of last year was -0.04337616. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Fuso Pharmaceutical Industries's current Net Income (TTM) was 2,011. Fuso Pharmaceutical Industries's current Cash Flow from Operations (TTM) was -6,224. ==> -6,224 <= 2,011 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1858/86026
=0.02159812

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=2462/78765.5
=0.03125734

Fuso Pharmaceutical Industries's gearing of this year was 0.02159812. Fuso Pharmaceutical Industries's gearing of last year was 0.03125734. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=57336/51684
=1.10935686

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=48342/44131
=1.09542045

Fuso Pharmaceutical Industries's current ratio of this year was 1.10935686. Fuso Pharmaceutical Industries's current ratio of last year was 1.09542045. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Fuso Pharmaceutical Industries's number of shares in issue this year was 8.539. Fuso Pharmaceutical Industries's number of shares in issue last year was 8.543. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=15995/62307
=0.25671273

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=16532/60562
=0.27297645

Fuso Pharmaceutical Industries's gross margin of this year was 0.25671273. Fuso Pharmaceutical Industries's gross margin of last year was 0.27297645. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=62307/81729
=0.76236097

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=60562/75802
=0.7989499

Fuso Pharmaceutical Industries's asset turnover of this year was 0.76236097. Fuso Pharmaceutical Industries's asset turnover of last year was 0.7989499. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Fuso Pharmaceutical Industries has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Fuso Pharmaceutical Industries (TSE:4538) has a Piotroski F-Score of 5 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Fuso Pharmaceutical Industries and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Fuso Pharmaceutical Industries' Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Fuso Pharmaceutical Industries ranks #375 out of 978 companies in the Drug Manufacturers industry, placing it in the top 38.3%.
Is Fuso Pharmaceutical Industries' Piotroski F-Score too high?
Fuso Pharmaceutical Industries' current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Fuso Pharmaceutical Industries' value of 5 is 0% at this industry median. Based on the distribution chart, Fuso Pharmaceutical Industries ranks #375 out of 978 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Fuso Pharmaceutical Industries has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fuso Pharmaceutical Industries' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Fuso Pharmaceutical Industries ranks #375 out of 978 companies for Piotroski F-Score. This puts Fuso Pharmaceutical Industries in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Fuso Pharmaceutical Industries' value of 5 is 0% at this benchmark. Historically, Fuso Pharmaceutical Industries' own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Fuso Pharmaceutical Industries has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fuso Pharmaceutical Industries's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Fuso Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fuso Pharmaceutical Industries's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuso Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Fuso Pharmaceutical Industries (TSE:4538) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,540.99, compared to a current price of 円2,071.00 — trading 18.5% below its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Drug Manufacturers industry median of 5.00. Fuso Pharmaceutical Industries' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Fuso Pharmaceutical Industries (TSE:4538), the current Piotroski F-Score is 5 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fuso Pharmaceutical Industries (TSE:4538) Overvalued in 2026?

Based on GuruFocus' analysis, Fuso Pharmaceutical Industries stock appears to be undervalued. The current stock price of 円2,071.00 is trading 18.5% below its estimated GF Value™ of 円2,540.99. GuruFocus considers Fuso Pharmaceutical Industries to be Modestly Undervalued.

Key valuation signals for TSE:4538:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: 円2,540.99 vs. price of 円2,071.00 (18.5% below fair value)
  • GF Score™: 51/100 with 5 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#375 of 978)

No single metric tells the full story. See the TSE:4538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fuso Pharmaceutical Industries Business Description

Address No. 10, No. 7-chome Doshomachi, Chuo-ku, OsaKa, JPN, 541-0045
Fuso Pharmaceutical Industries Ltd. is engaged in the manufacture and sale of pharmaceuticals and medical equipment. The company's main products are transfusion fluid and artificial kidney dialysis fluid. Company also includes real estate segment.
51GF Score

Get the complete analysis for TSE:4538

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,071.00
Price
円2,540.99
GF Value